Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Authors:
- Patricia J. KellerPKPatricia J. Keller
- Elizabeth J. AdamsEAElizabeth J. Adams
- Rentian WuRWRentian Wu
- Alexandre CôtéACAlexandre Côté
- Shilpi AroraSAShilpi Arora
- Nico CantoneNCNico Cantone
- Rosana MeyerRMRosana Meyer
- Jennifer A. MertzJMJennifer A. Mertz
- Victor GehlingVGVictor Gehling
- Jike CuiJCJike Cui
- Jacob I. StuckeyJSJacob I. Stuckey
- Avinash KhannaAKAvinash Khanna
Open Access
- 4 June 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (15) , 2501-2517
Abstract
Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin remodeling complex subunit ARID1A occur frequently in advanced urothelial, endometrial, and ovarian clear cell carcinomas, creating an alternative chromatin state that may be exploited therapeutically. The histone methyltransferase EZH2 has been previously identified as targetable vulnerability in the context of ARID1A mutations. In this study, we describe the discovery of tulmimetostat, an orally available, clinical stage EZH2 inhibitor, and it elucidates the aspects of its application potential in ARID1A mutant tumors. Tulmimetostat administration achieved efficacy in multiple ARID1A mutant bladder, ovarian, and endometrial tumor models and improved cisplatin response in chemotherapy-resistant models. Consistent with its comprehensive and durable level of target coverage, tulmimetostat demonstrated greater efficacy than other PRC2-targeted inhibitors at comparable or lower exposures in a bladder cancer xenograft mouse model. Tulmimetostat mediated extensive changes in gene expression, in addition to a profound reduction in global H3K27me3 levels in tumors. Phase I clinical pharmacokinetic and pharmacodynamic data indicated that tulmimetostat exhibits durable exposure and profound target engagement. Importantly, a tulmimetostat controlled gene expression signature identified in whole blood from a cohort of 32 patients with cancer correlated with tulmimetostat exposure, representing a pharmacodynamic marker for the assessment of target coverage for PRC2-targeted agents in the clinic. Collectively, these data suggest that tulmimetostat has the potential to achieve clinical benefit in solid tumors as a monotherapy but also in combination with chemotherapeutic agents, and may be beneficial in various indications with recurrent ARID1A mutations. Significance: The EZH2 inhibitor tulmimetostat achieves comprehensive target inhibition in ARID1A mutant solid tumor models and cancer patients that can be assessed with a pharmacodynamic gene signature in peripheral blood.Keywords
All Related Versions
Funding Information
- Constellation Pharmaceuticals
- MorphoSys
This publication has 48 references indexed in Scilit:
- The mutational landscape of chromatin regulatory factors across 4,623 tumor samplesGenome Biology, 2013
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Proceedings of the National Academy of Sciences, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomasThe Journal of Pathology, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic TransformationCancer Cell, 2010
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005